As branded insulins like the insulin glargine combination soliquoa from Sanofi (India) become available in India, they will face fierce competition from the existing insulins and upcoming biosimilars, due to the price sensitive nature of the T2D insulin market, says GlobalData, a leading data and analytics company.
Sanofi launches new long-acting insulin drug in India
Mylan Pharms Inc Biological Insulin Glargine-Yfgn Receives Approval in US